{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuromuscular+Agents&page=2", "query": { "condition": "Neuromuscular Agents", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuromuscular+Agents&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T04:55:19.054Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07122193", "title": "A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuromuscular Agents", "Peripheral Nervous System Agents", "Physiological Effects of Drugs", "Acetylcholine Release Inhibitors", "Membrane Transport Modulators", "Molecular Mechanisms of Pharmacological Action", "Cholinergic Agents", "Neurotransmitter Agents", "incobotulinumtoxinA", "Botulinum Toxins, Type A" ], "interventions": [ { "name": "NT 201", "type": "DRUG" }, { "name": "NT 201 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merz North America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-08-27", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07122193" }, { "nct_id": "NCT03346057", "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Reversal of Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 16 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Rocuronium", "type": "DRUG" }, { "name": "Vecuronium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2017-12-20", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03346057" }, { "nct_id": "NCT02728726", "title": "Sugammadex vs Placebo to Prevent Residual Neuromuscular Block", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "General Surgery" ], "interventions": [ { "name": "Sugammadex", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 260, "start_date": "2016-06", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Houston, Texas", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728726" }, { "nct_id": "NCT03585348", "title": "Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuromuscular Blockade", "Residual Curarisation, Postoperative", "Surgery Under General Anaesthesia" ], "interventions": [ { "name": "Neuromuscular blocking agents", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265537, "start_date": "2018-06-29", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585348" }, { "nct_id": "NCT05794503", "title": "Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urinary Retention Postoperative", "Laparoscopic Cholecystectomy", "Neuromuscular Blockade", "Sugammadex", "Neostigmine", "Neuromuscular Blocking Agents", "Physiological Effects of Drugs" ], "interventions": [ { "name": "Neostigmine", "type": "DRUG" }, { "name": "Sugammadex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 235, "start_date": "2023-09-11", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05794503" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT03520517", "title": "Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis", "ALS", "Lou Gehrig Disease", "Lou Gehrig's Disease", "Lou-Gehrigs Disease", "Motor Neuron Disease, Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "BHV-0223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-02-02", "completion_date": "2018-10-08", "has_results": false, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 5, "location_summary": "Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cordova", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520517" }, { "nct_id": "NCT00017771", "title": "Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections", "Peripheral Nervous System Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 100, "start_date": "2001-06", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017771" }, { "nct_id": "NCT03962725", "title": "Avoiding Neuromuscular Blockers to Reduce Complications", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Respiratory Failure", "Respiratory Infection", "Aspiration Pneumonia", "Pneumonitis", "Atelectasis", "Bronchospasm" ], "interventions": [ { "name": "Neuromuscular Blocking Agents", "type": "DRUG" }, { "name": "Anesthetic Adjuncts", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-08-07", "completion_date": "2022-12-19", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03962725" }, { "nct_id": "NCT07336446", "title": "A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AZD9750", "type": "DRUG" }, { "name": "AZD5305", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 300, "start_date": "2026-01-27", "completion_date": "2029-01-26", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-06-11T04:55:19.054Z", "location_count": 8, "location_summary": "Duarte, California • San Francisco, California • Tampa, Florida + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07336446" } ] }